A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma
Enrolling By Invitation
18 years - 90 years
All
Phase
2
5 participants needed
1 Location
Brief description of study
Non-Hodgkin lymphoma is a disease that can be treated effectively with chemotherapy and immunotherapy, but relapses can occur. The purpose of this study is to research the use of a new radioimmunotherapy drug called Betalutin®. Betalutin® is made by using a new antibody, called lilotomab, and attaching a radioactive molecule (radioisotope) called Lutetium-177. The radioisotope Lutetium-177 may be more suitable for radioimmunotherapy than the radioisotopes that have previously been used for non-Hodgkin lymphoma. The Betalutin® binds to an area on the surface of the cancer cells called CD37. This therapy is intended to target the cancer cells with the radioactivity, thereby irradiating them inside the body.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: non-Hodgkin lymphoma
-
Age: 18 years - 90 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 832864
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
